Your browser is no longer supported. Please, upgrade your browser.
Fulcrum Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own0.30% Shs Outstand32.64M Perf Week-16.67%
Market Cap948.56M Forward P/E- EPS next Y-2.70 Insider Trans-44.06% Shs Float17.56M Perf Month-25.27%
Income-73.30M PEG- EPS next Q-0.65 Inst Own74.30% Short Float11.76% Perf Quarter129.71%
Sales15.20M P/S62.41 EPS this Y29.50% Inst Trans10.37% Short Ratio0.60 Perf Half Y97.94%
Book/sh3.40 P/B6.78 EPS next Y-4.20% ROA-51.80% Target Price34.86 Perf Year110.80%
Cash/sh3.05 P/C7.55 EPS next 5Y6.40% ROE-66.80% 52W Range6.85 - 33.10 Perf YTD96.75%
Dividend- P/FCF- EPS past 5Y- ROI-75.20% 52W High-29.69% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low239.71% ATR2.08
Employees73 Current Ratio5.70 Sales Q/Q120.00% Oper. Margin- RSI (14)38.64 Volatility7.93% 7.82%
OptionableYes Debt/Eq0.00 EPS Q/Q8.40% Profit Margin- Rel Volume0.13 Prev Close23.04
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume3.44M Price23.27
Recom2.00 SMA20-14.13% SMA50-10.59% SMA20059.32% Volume103,803 Change1.00%
Aug-11-21Upgrade Morgan Stanley Equal-Weight → Overweight $12 → $34
Apr-26-21Resumed Credit Suisse Outperform $26
Mar-22-21Initiated Credit Suisse Outperform $26
Mar-02-21Initiated Stifel Buy $18
Oct-16-20Initiated Piper Sandler Overweight $22
Aug-12-20Reiterated H.C. Wainwright Buy $28 → $20
Aug-12-20Downgrade Morgan Stanley Overweight → Equal-Weight $11
Aug-12-20Downgrade BofA Securities Neutral → Underperform $11
Jun-19-20Downgrade BofA/Merrill Buy → Neutral $19 → $23
Jun-17-20Initiated BTIG Research Buy $27
Oct-03-19Initiated H.C. Wainwright Buy $21
Aug-12-19Initiated BofA/Merrill Buy $19
Oct-14-21 10:05AM  
Oct-01-21 07:00AM  
Sep-21-21 01:59PM  
Sep-20-21 07:00AM  
Sep-10-21 07:00AM  
Sep-08-21 07:00AM  
Sep-02-21 07:00AM  
Aug-23-21 06:47AM  
Aug-16-21 04:01PM  
Aug-12-21 01:33AM  
Aug-11-21 10:09PM  
Aug-10-21 04:24PM  
Aug-04-21 07:00AM  
Aug-03-21 03:00PM  
Jul-30-21 11:14AM  
Jul-01-21 01:25AM  
Jun-24-21 07:00AM  
Jun-21-21 07:00AM  
May-12-21 04:19PM  
May-07-21 07:00AM  
May-06-21 08:55AM  
Apr-29-21 07:00AM  
Apr-09-21 01:15PM  
Mar-24-21 09:29AM  
Mar-18-21 11:30AM  
Mar-04-21 08:25AM  
Feb-26-21 07:00AM  
Feb-19-21 07:00AM  
Feb-17-21 02:47AM  
Jan-22-21 04:00PM  
Jan-19-21 10:34PM  
Jan-06-21 07:00AM  
Dec-09-20 09:43PM  
Dec-05-20 10:00AM  
Dec-03-20 08:00AM  
Nov-16-20 03:18AM  
Nov-13-20 07:30AM  
Nov-10-20 11:30AM  
Nov-09-20 08:31AM  
Nov-04-20 04:01PM  
Nov-03-20 07:00AM  
Oct-31-20 08:00AM  
Oct-05-20 07:00AM  
Oct-01-20 07:00AM  
Sep-25-20 02:15PM  
Sep-08-20 07:00AM  
Aug-18-20 02:49PM  
Aug-11-20 07:01AM  
Aug-10-20 09:43AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Jul-28-20 07:54AM  
Jul-21-20 07:30AM  
Jun-24-20 08:56AM  
Jun-12-20 06:45PM  
Jun-10-20 07:01AM  
May-21-20 07:00AM  
May-14-20 09:42AM  
May-13-20 09:31PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
Apr-13-20 07:00AM  
Apr-02-20 07:00AM  
Mar-24-20 02:20PM  
Mar-05-20 07:00AM  
Feb-28-20 07:00AM  
Feb-26-20 07:00AM  
Feb-25-20 08:00AM  
Feb-20-20 08:01AM  
Jan-29-20 08:01AM  
Jan-06-20 07:00AM  
Dec-30-19 07:30AM  
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and -thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stuart BryanSee RemarksAug 11Option Exercise7.8428,000219,52028,000Aug 12 04:20 PM
Stuart BryanSee RemarksAug 11Sale23.7528,000665,0000Aug 12 04:20 PM
Moxham ChristopherChief Scientific OfficerAug 10Option Exercise7.8451,785405,99431,071Aug 12 04:20 PM
Stuart BryanSee RemarksAug 10Option Exercise7.8432,000250,88032,000Aug 12 04:20 PM
Moxham ChristopherChief Scientific OfficerAug 10Sale17.6051,785911,4160Aug 12 04:20 PM
Stuart BryanSee RemarksAug 10Sale17.5032,000560,0000Aug 12 04:20 PM
Thomson Peter G.VP Finance & AccountingJun 28Buy9.002,30020,7002,300Jun 29 04:15 PM
Oltmans Curtis GaleSVP, General CounselJun 28Buy9.011,0889,8031,088Jun 29 04:16 PM
Morabito ChristopherChief Medical OfficerJun 28Buy9.161,10010,0761,100Jun 29 04:16 PM
GERAGHTY JAMES ADirectorJun 28Buy9.1610,00091,60090,714Jun 29 04:15 PM
Gould Robert JSee RemarksMar 16Sale12.437899,806506,630Mar 17 04:30 PM
Gould Robert JSee RemarksMar 15Sale12.139,211111,773507,419Mar 17 04:30 PM
Thomson Peter G.VP Finance & AccountingFeb 22Option Exercise7.845,00039,20020,212Feb 24 04:30 PM
Thomson Peter G.VP Finance & AccountingFeb 22Sale14.725,00073,58215,212Feb 24 04:30 PM
Gould Robert JSee RemarksFeb 16Sale14.278,215117,197516,630Feb 18 04:30 PM
Thomson Peter G.VP Finance & AccountingJan 21Sale14.006,60792,49815,212Jan 25 04:30 PM
Gould Robert JSee RemarksJan 20Sale12.0810,000120,826524,845Jan 22 04:30 PM